From Yahoo Finance: 2025-05-10 08:45:00

AbbVie and Gilead are strong dividend stocks with impressive track records and innovative abilities. AbbVie is a Dividend King with 53 consecutive years of payout increases. Gilead dominates the HIV market and is expanding into oncology. Both companies offer above-average yields and long-term growth potential.

AbbVie’s success is attributed to its immunology drugs, Skyrizi and Rinvoq, which are driving rapid sales growth. The company navigated the patent cliff for Humira, proving its resilience. With a diverse product lineup and strong pipeline, AbbVie is poised for continued success and dividend growth.

Gilead’s HIV business remains strong, with top-selling therapies like Biktarvy and Descovy. The company is diversifying into oncology and COVID-19 treatments. With a solid dividend history and ongoing innovations, Gilead is a reliable choice for income-seeking investors.

Both AbbVie and Gilead offer forward yields above 3%, surpassing the S&P 500 average. These dividend stocks are worth holding long-term. Consider these top performers for consistent payouts and growth potential in your investment portfolio.

Read more: 2 High-Yield Dividend Stocks to Buy in May and Hold Forever